Congressional watchdog advises HHS to implement 'post-marketing' incentives to address dwindling antibiotic development efforts
With the Covid-19 crisis expected to shore up antibiotic use with opportunistic secondary bacterial infections — and potentially exacerbate the rate antibiotic resistance — a congressional watchdog has put together a list of recommendations to sort out the challenges affecting antibiotic stewardship, track rates of drug resistance, and fix the ‘broken’ market for antibiotics.
While bacterial pathogens mutate and grow resistant to the existing crop of antibiotics, driven by unbridled use in humans and livestock — the industry players contributing to the arsenal of antimicrobials are fast dwindling, and the pipeline for new antibiotics is embarrassingly sparse, the WHO has warned.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
